Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07160725 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors
A Phase 1 study of Solid Tumours, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 315
- Enrollment target
- 19
- Study locations
NCT07160725: Recruiting Phase 1 study of Solid Tumours, sponsored by Bristol-Myers Squibb.
NCT07160725 is a Phase 1 study of Solid Tumours that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 315 participants, above the 111-participant average among 9 other Solid Tumours trials with a reported enrollment target (184% higher). The trial reports 19 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07160725, a Phase 1 study of Solid Tumours, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 315 participants
- Enrollment target
- 19
- Study locations
Study Summary
A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
Conditions Studied
Interventions
- DRUG BMS-986517
Study Locations (19)
California
- Local Institution - 0033 - Irvine
- USC/Norris Comprehensive Cancer Center - Los Angeles
- Local Institution - 0021 - Orange
Other
- Copenhagen University Hospital Rigshospitalet - Copenhagen
- Local Institution - 0027 - Madrid
- Local Institution - 0023 - Madrid
Texas
- START - Dallas Fort Worth - Fort Worth
- START San Antonio - San Antonio
Barcelona [Barcelona]
- Local Institution - 0022 - Badalona
- Local Institution - 0024 - Barcelona
Pennsylvania
- Local Institution - 0008 - Pittsburgh
South Dakota
- Sanford Cancer Center - Sioux Falls
Utah
- START Mountain Region - West Valley City
Washington
- Local Institution - 0028 - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2025-10-15 |
| Est. Completion | 2028-08-01 |
| Phase | Phase 1 |
What NCT07160725 shows while recruiting
NCT07160725 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, above the 111-participant average among 9 other Solid Tumours trials with a reported enrollment target (184% higher).
The record links to 1 condition, with Solid Tumours appearing as the primary indexed condition, and to 1 intervention - of which BMS-986517 is the first listed.
NCT07160725 lists 19 locations in 13 states (California, Other, Texas).
Frequently Asked Questions
What is clinical trial NCT07160725 about?
NCT07160725 is a clinical study titled "A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors". A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors
What is the current status of trial NCT07160725?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 315 participants. The study started on 2025-10-15. Estimated completion is 2028-08-01.
What conditions does trial NCT07160725 study?
This clinical trial studies the following conditions: Solid Tumours.
What interventions are being tested in trial NCT07160725?
The interventions under investigation include: BMS-986517 (DRUG).
Who is sponsoring clinical trial NCT07160725?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07160725 being conducted?
This trial has 19 study locations across California, Pennsylvania, South Dakota, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumours
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07160725's enrollment target sits among peer trials
315 2nd of 9 the highest of 9 other Solid Tumours trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumours trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in People With Advanced Cancer (Solid Tumours) to Test Different Doses of BI 3810944 and to Find Out Whether it Helps
RECRUITING · Phase 1
-
A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors
RECRUITING · Phase 1
-
Ispinesib In Combination With Carboplatin In Patients With Solid Tumors
COMPLETED · Phase 1
-
To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers
COMPLETED · Phase 1
-
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
COMPLETED · Phase 1
-
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI